NCI Cancer Bulletin: A Trusted Source for Cancer Research NewsNCI Cancer Bulletin: A Trusted Source for Cancer Research News
May 2, 2006 • Volume 3 / Number 18 E-Mail This Document  |  Download PDF  |  Bulletin Archive/Search  |  Subscribe

NCI Cancer Bulletin Archive

Page Options

  • Print This Page
  • Print This Document
  • View Entire Document
  • Email This Document
  • View/Print PDF

The information and links on this page are no longer being updated and are provided for reference purposes only.

Featured Clinical TrialFeatured Clinical Trial

Targeted Treatment for Recurrent or Progressive Lung Cancer

NCI Releases Report on Cancer Incidence in Middle East
NCI has released a new monograph on cancer incidence in Cyprus, Egypt, Israel, and Jordan, as part of the Joint Cancer Registration Project of the Middle East Cancer Consortium. The monograph is available at, under "Cancer Registry Project." Look for more information on the monograph in an upcoming issue of the NCI Cancer Bulletin.
Name of the Trial
Phase II Study of Sorafenib in Patients with Recurrent or Progressive Stage IV Non-Small-Cell Lung Cancer (NCI-05-C-0049). See the protocol summary at This trial was originally featured in the October 18, 2005, issue of the NCI Cancer Bulletin.

Principal Investigator
Dr. Martin Gutierrez, NCI CCR

Why This Trial Is Important
Lung cancer is the leading cause of cancer-related death in the United States, and it has often spread (metastasized) by the time it is diagnosed. For patients with metastatic lung cancer, the prognosis is poor. Consequently, new and more effective treatments for metastatic lung cancer are needed.

In this clinical trial, researchers are testing a new drug called sorafenib to see if it can cause tumors to shrink or disappear in patients with metastatic non-small-cell lung cancer (NSCLC) that has recurred or progressed after previous treatment with chemotherapy. Sorafenib inhibits a protein called Raf kinase, which helps promote cell proliferation. Blocking Raf kinase activity may halt the spread of cancer cells.

Sorafenib also inhibits two other proteins named vascular endothelial growth factor receptors 2 and 3 (VEGFR2 and VEGFR3), which help tumors form new blood vessels (a process called angiogenesis). By blocking VEGFR2 and VEGFR3 activity, sorafenib may help cut off the blood supply to tumors and cause them to die.

"Sorafenib is a molecularly targeted oral medication with both antiproliferative and antiangiogenic properties," said Dr. Gutierrez. "It has shown some promising results against NSCLC in an earlier phase I study, and it appears to be well tolerated. Most of the toxicity that we have seen has been mild and easy to control."

Who Can Join This Trial
Researchers seek to enroll up to 40 patients aged 18 or over with recurrent or progressive stage IV NSCLC. See the list of eligibility criteria at

Study Site and Contact Information
This study is taking place at the NIH Clinical Center in Bethesda, Md. For more information, call the NCI Clinical Studies Support Center (CSSC) at 1-888-NCI-1937. The call is toll free and confidential.

An archive of "Featured Clinical Trial" columns is available at